Cepadacursen sodium

N/A

Report date: 2026/01/05 10:35:02
NME

Base Information

Drug NameCepadacursen sodium
Drug Alias NameLNA-PCSK9-GalNacLNA-PCSK -9CiVi-007
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCivi Biopharma Inc
Active IndicationsN/A
Inactive IndicationsHypercholesterolemia

Other Information

ATC CodeN/A
Related LinksN/A